All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM | DEC 2025 | DEC 2024 ~8.7:1 split | DEC 2023 2:1 split | DEC 2022 | DEC 2021 |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $0 | $0 | $0 | $1 | $2 | $19 |
| General & Administrative | $46 | $48 | $46 | $40 | $29 | $27 |
| Research & Development | $163 | $172 | $163 | $90 | $59 | $57 |
| Total Operating Expenses | $209 | $210 | $209 | $243 | $87 | $84 |
| Operating Income | -$209 | -$210 | -$209 | -$242 | -$85 | -$66 |
| Non-Operating | ||||||
| Net Interest Expense | $21 | $25 | $21 | $6 | $1 | $0 |
| Other Non-Operating Income (Expense) | -$21 | $29 | -$21 | -$103 | -$0 | -$0 |
| EBT (Earnings Before Tax) | -$208 | -$155 | -$208 | -$339 | -$84 | -$66 |
| Income Tax Expense | $0 | -$0 | $0 | -$0 | -$0 | $0 |
| Net Income | ||||||
| Net Income | -$208 | -$155 | -$208 | -$339 | -$84 | -$66 |
| Per Share Data | ||||||
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.13 | $0.69 | $7.13 |
| EPS (Basic) | -$3.45 | -$1.98 | -$3.45 | $13.76 | -$24.86 | -$25.02 |
| EPS (Diluted) | -$3.45 | -$1.98 | -$3.45 | $13.76 | -$24.86 | -$25.02 |
| Weighted Avg Shares (Basic) | – | – | – | 6.9M | 3.4M | 2.6M |
| Weighted Avg Shares (Diluted) | – | – | – | 6.9M | 3.4M | 2.6M |
| Shares Outstanding | 60.3M | 78.2M | 60.3M | 6.9M | 3.4M | 2.6M |
Spyre Therapeutics (SYRE) financials: revenue, profit and margins
Spyre Therapeutics (SYRE) generated about n/a in revenue and -$264 million in net income over the trailing twelve months, growing at roughly -28.2% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Spyre Therapeutics profitable?+
Spyre Therapeutics reported about -$264 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
How fast is Spyre Therapeutics growing?+
Spyre Therapeutics's revenue has compounded at roughly -28.2% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside SYRE's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 27 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 4 Nov 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Pharmaceutical Preparations · Pick stocks to compare with SYRE
Held by ETFs
SYRE is in 74 US ETFs. The largest of them, with SYRE's weight in each:
Spot a number that looks wrong? Check it in SYRE's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing SYRE
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.